Sickle Cell Disease patients and the use of disease-modifying treatments

New disease-modifying treatments (DMTs), namely, crizanlizumab, L-glutamine, and voxelotor, have recently been approved.

The big any-day-now biotech news we’re keeping an eye on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here

January 17, 2024

Study shines light on the well-being challenges faced by women in healthcare

Study reviews the well-being of women in healthcare, highlighting the impact of work-life balance, professional autonomy, and supportive environments on their mental health and job

February 26, 2024

New obesity biotech Syntis Bio launches with early-stage alternative to GLP-1s

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.